JP2024521757A5 - - Google Patents
Info
- Publication number
- JP2024521757A5 JP2024521757A5 JP2023572618A JP2023572618A JP2024521757A5 JP 2024521757 A5 JP2024521757 A5 JP 2024521757A5 JP 2023572618 A JP2023572618 A JP 2023572618A JP 2023572618 A JP2023572618 A JP 2023572618A JP 2024521757 A5 JP2024521757 A5 JP 2024521757A5
- Authority
- JP
- Japan
- Prior art keywords
- oeg
- cooh
- insulin analog
- human insulin
- desb30 human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110570030 | 2021-05-24 | ||
| CN202110570030.6 | 2021-05-24 | ||
| PCT/CN2022/094392 WO2022247773A1 (en) | 2021-05-24 | 2022-05-23 | A novel acylated insulin analog |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024521757A JP2024521757A (ja) | 2024-06-04 |
| JP2024521757A5 true JP2024521757A5 (enExample) | 2025-06-03 |
Family
ID=84115321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023572618A Pending JP2024521757A (ja) | 2021-05-24 | 2022-05-23 | 新規なアシル化インスリンアナログ |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240374692A1 (enExample) |
| EP (1) | EP4347632A4 (enExample) |
| JP (1) | JP2024521757A (enExample) |
| KR (1) | KR20240013778A (enExample) |
| CN (1) | CN115385843A (enExample) |
| AU (1) | AU2022283328A1 (enExample) |
| CA (1) | CA3217734A1 (enExample) |
| WO (1) | WO2022247773A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026517987A (ja) * | 2023-05-24 | 2026-06-02 | ザ ユナイテッド バイオテクノロジー（ヘンチン）シーオー．，エルティーディー． | インスリン誘導体およびその使用 |
| WO2025098457A1 (zh) * | 2023-11-07 | 2025-05-15 | 甘李药业股份有限公司 | 用于降糖的酰化胰岛素 |
| CN122555570A (zh) * | 2023-11-08 | 2026-08-11 | 甘李药业股份有限公司 | 包含胰岛素衍生物的药物组合物的治疗用途 |
| CN117756914B (zh) * | 2023-12-15 | 2024-09-03 | 瀚晖制药有限公司 | 依柯胰岛素的制备方法 |
| CN118063589A (zh) * | 2024-02-04 | 2024-05-24 | 乐普健糖药业(重庆)有限公司 | 一种超长效胰岛素类似物及其制备方法和用途 |
| WO2025228255A1 (zh) * | 2024-04-28 | 2025-11-06 | 正大天晴药业集团股份有限公司 | 酰化人胰岛素类似物 |
| WO2026109062A1 (zh) * | 2024-11-25 | 2026-05-28 | 甘李药业股份有限公司 | 含酰化胰岛素的药物组合物 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1888104A2 (en) * | 2005-05-26 | 2008-02-20 | Novo Nordisk A/S | Acylated insulin with high purity |
| WO2007104737A1 (en) * | 2006-03-13 | 2007-09-20 | Novo Nordisk A/S | Acylated single chain insulin |
| CN101437849B (zh) * | 2006-05-09 | 2015-09-30 | 诺沃-诺迪斯克有限公司 | 胰岛素衍生物 |
| AU2008288413B2 (en) * | 2007-08-15 | 2013-09-26 | Novo Nordisk A/S | Insulin analogues with an acyl and aklylene glycol moiety |
| HUE032284T2 (en) * | 2008-03-18 | 2017-09-28 | Novo Nordisk As | Protease-stabilized, acylated insulin analogues |
| CN102149411A (zh) * | 2008-09-12 | 2011-08-10 | 诺沃—诺迪斯克有限公司 | 酰化肽或蛋白的方法 |
| CN104788556A (zh) * | 2011-12-15 | 2015-07-22 | 上海恒瑞医药有限公司 | 人胰岛素类似物及其酰化衍生物 |
| WO2014009316A1 (en) * | 2012-07-09 | 2014-01-16 | Novo Nordisk A/S | Novel use of insulin derivatives |
| CA2926701A1 (en) | 2013-10-07 | 2015-04-16 | Novo Nordisk A/S | Novel derivative of an insulin analogue |
| AR099569A1 (es) * | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
| US9856292B2 (en) * | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
| EP3341401A1 (en) * | 2015-08-25 | 2018-07-04 | Novo Nordisk A/S | Novel insulin derivatives and the medical uses hereof |
| BR112018002416A2 (pt) * | 2015-08-25 | 2018-09-18 | Novo Nordisk As | derivados de insulina e seus usos médicos |
| US10815287B2 (en) | 2016-08-02 | 2020-10-27 | Jiangsu Hengrui Medicine Co., Ltd. | Acylated derivative of human insulin or analogue thereof |
| WO2019149245A1 (zh) * | 2018-02-01 | 2019-08-08 | 江苏恒瑞医药股份有限公司 | 含人胰岛素类似物的酰化衍生物的药物组合物及其制备方法 |
| BR112022013009A2 (pt) * | 2019-12-30 | 2022-09-06 | Gan & Lee Pharmaceuticals Co Ltd | Derivados de insulina, composição farmacêutica, uso do derivado da insulina e métodos para tratar ou prevenir diabetes, para aumentar a capacidade de um derivado de insulina e para aumentar a potência de um derivado de insulina |
| JP2020117542A (ja) * | 2020-05-07 | 2020-08-06 | ノヴォ ノルディスク アー／エス | 錠剤コアとポリビニルアルコールコーティングとを含む経口インスリン投与のための医薬組成物 |
-
2022
- 2022-05-23 CA CA3217734A patent/CA3217734A1/en active Pending
- 2022-05-23 AU AU2022283328A patent/AU2022283328A1/en active Pending
- 2022-05-23 CN CN202210567043.2A patent/CN115385843A/zh active Pending
- 2022-05-23 US US18/563,090 patent/US20240374692A1/en active Pending
- 2022-05-23 JP JP2023572618A patent/JP2024521757A/ja active Pending
- 2022-05-23 KR KR1020237044398A patent/KR20240013778A/ko active Pending
- 2022-05-23 WO PCT/CN2022/094392 patent/WO2022247773A1/en not_active Ceased
- 2022-05-23 EP EP22810498.0A patent/EP4347632A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5249016B2 (ja) | タキサン類の高分子結合体 | |
| JP2019526537A5 (enExample) | ||
| CN1187361C (zh) | 磷酸取代的苯并氮杂卓酮－n－醋酸衍生物、制法和药物 | |
| JP2022509568A5 (enExample) | ||
| EP2344529B1 (fr) | Nouveaux composes octapeptidiques derives de la somatostatine et leur utilisation therapeutique | |
| JP2012512901A5 (enExample) | ||
| CA3084688A1 (fr) | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes | |
| WO2019110773A1 (fr) | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes | |
| JP2015531789A5 (enExample) | ||
| JP2010504934A5 (enExample) | ||
| WO2019110774A1 (fr) | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes | |
| JP2016523241A5 (enExample) | ||
| LU87633A1 (fr) | Derives peptidiques | |
| CA3166495A1 (en) | Insulin derivative | |
| RU2014127270A (ru) | Аналог человеческого инсулина и его ацилированное производное | |
| EP2361241A1 (fr) | Procede de synthese d'un omega-aminoacide ou ester a partir d'un acide ou ester gras mono-insature | |
| LU86697A1 (fr) | Nouveaux derives de la calcitonine,leur preparation et leur utilisation comme medicaments | |
| JP2019526537A (ja) | ヒトインスリンまたはそのアナログのアシル化誘導体 | |
| RU2020108281A (ru) | Новые ацилированные аналоги инсулина и варианты их применения | |
| JP2023516886A5 (enExample) | ||
| EP3740227A1 (fr) | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide | |
| WO2013072466A1 (fr) | Procede de fabrication de composes comprenant des fonctions nitriles | |
| WO2019243628A1 (fr) | Composition injectable a ph 7 comprenant un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes et au moins une insuline basale presentant au moins un effet prandial et un effet basal | |
| JP2013527178A5 (enExample) | ||
| EP0511903A2 (fr) | Conjugué de calcitonine et de polyéthylène glycol |